CD4 and cutaneous mastocytosis: Further, the risk ratio of the incidence of CM among persons with CD4+ T cell counts between 100 and 200 cells/μL receiving placebo or no intervention was 1.15 times compared to those receiving antifungal treatment (95%CI: 0.16–8.13, p = 0.97, I2 = 0%; three studies; 140 persons).